Basic Information
| LncRNA/CircRNA Name | FTX |
| Synonyms | FTX, LINC00182, MIR374AHG, NCRNA00182 |
| Region | GRCh38_X:73946555-74293574 |
| Ensemble | ENSG00000230590 |
| Refseq | NR_028379 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, RIP, etc. |
| Sample | CRC tissues, cell lines (HT29, LS513, SW480, HCT8, HCT116, FHC) |
| Expression Pattern | up-regulated |
| Function Description | Overexpression of lncRNA FTX was significantly associated with the bigger tumor diameter, the advanced TNM stage, the lymph node, and distant metastasis, and also predicted poor prognosis of patients with CRC. FTX directly interacted with miR-215 and suppressed miR-215 expression. The results showed that patients with higher FTX levels had shorter overall survival time than those with lower FTX levels. |
| Pubmed ID | 29925853 |
| Year | 2018 |
| Title | LncRNA FTX sponges miR-215 and inhibits phosphorylation of vimentin for promoting colorectal cancer progression. |
External Links
| Links for FTX | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |